Artiva Biotherapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Artiva Biotherapeutics, Inc. (ARTV) had Deferred Tax Assets, Operating Loss Carryforwards of $54.93 million as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-10
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $54.93M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $29.69M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $20.42M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $54.93M 10-K · filed 2026-03-10 |
| 2024-12-31 | $29.69M 10-K · filed 2026-03-10 |
| 2023-12-31 | $20.42M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |